# Expanding Medication Assisted Therapies in Central Asia

> **NIH NIH R01** · YALE UNIVERSITY · 2023 · $572,514

## Abstract

Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in
people who inject drugs (PWID) and their sexual partners. Scaling up opioid agonist therapies (OAT) in CA is
the most cost-effective strategy to prevent new HIV infections, and more effective when combined with
antiretroviral therapy (ART). CA countries have especially low OAT (and ART) coverage and are uniquely
impacted by their proximity to opioid trade routes, a myriad of patient, provider, healthcare and policy barriers
and suboptimal implementation. CA countries share a similar rigid Semashko healthcare system, which can be
especially challenging for implementing evidence-based practices (EBPs). Moreover, the HIV treatment cascade
differs in the three countries of Kazakhstan (KZ), Kyrgyzstan (KY) and Tajikistan (TJ), generally with low levels
of case detection, ART prescription and viral suppression. They also differ by OAT coverage, with all being
suboptimal and well-below international targets for the 120,500, 25,000 and 22,500 PWID, respectively. We
propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to
scale-up OAT in three diverse CA countries guided by the EPIS (Exploration-Planning-Implementation-
Sustainment) framework. Using our experiences with NIATx to scale-up OAT, we will use the EPIS framework
where we will first assess the barriers and facilitators to OAT scale-up, including the inner and outer contexts as
well as bridging factors. These findings will guide preparation and implementation efforts using NIATx.
Collaborative learning is key feature of NIATx that can be used in diverse contexts and is an iterative process
that promotes change. Understanding the trajectories of implementation, a core feature of EPIS, may in this
context emerge through creating communities of practice, especially when cohesion and/or competence evolves
through this process, and may guide other healthcare delivery challenges in the region (e.g., HIV, TB). Using
NIATx to build important regional expertise and competence and understanding implementation trajectories in
this context should help support OAT program sustainability. As part of our implementation and sustainability
plan, and consistent with NIATx, we will convene stakeholder meetings to bridge inner and outer factors to guide
initial and ongoing implementation, review findings from our studies and use information to inform policies for
expanding OAT in each CA country. These meeting will inform implementation and guide policy changes to
promote sustainability. Significance is justified by the regional needs to prevent HIV in PWID and their sexual
partners and the lack of scale-up of EBPs. Innovation is enhanced not only by using NIATx in a new context, but
by more comprehensively understanding scale-up trajectories in this context. Success is likely to be high given
the experience of the US and Central Asian teams, their previous collaborativ...

## Key facts

- **NIH application ID:** 10693856
- **Project number:** 5R01DA054851-02
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** FREDERICK LEWIS ALTICE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $572,514
- **Award type:** 5
- **Project period:** 2022-09-01 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10693856

## Citation

> US National Institutes of Health, RePORTER application 10693856, Expanding Medication Assisted Therapies in Central Asia (5R01DA054851-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10693856. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*